化合物 Loxoprofen sodium (dihydrate)|T60704|TargetMol

Loxoprofen sodium (dihydrate)
226721-96-6

￥13800 50mg 起订

￥17500 100mg 起订

￥10600 25mg 起订

上海更新日期：2024-09-30

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 Loxoprofen sodium (dihydrate)

英文名称：: Loxoprofen sodium (dihydrate)

CAS号：: 226721-96-6

品牌：: TargetMol

产地：: 美国

保存条件：: Shipping with blue ice.

产品类别：: 抑制剂

货号：: T60704

Product Introduction

Bioactivity

名称	Loxoprofen sodium (dihydrate)
描述	Loxoprofen sodium dihydrate is a non-steroidal, orally active anti-inflammatory agent that has analgesic and anti-pyretic properties. Loxoprofen sodium dihydrate exhibits antitumor activity which also can reduce atherosclerosis. Loxoprofen sodium dihydrate is a nonselective inhibitor of COX with IC 50 s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively [1] [2] [3] [4].
体外活性	Loxoprofen sodium dihydrate, an anti-inflammatory prodrug (NSAID), is a nonselective COX inhibitor with IC 50 s of 6.5 and 13.5 μM for COX-1 and COX-2 in human whole blood assays, respectively [1]. Loxoprofen (LOX) sodium dihydrate is a non-selective cyclooxygenase inhibitor that is widely used for the reasearch of pain and inflammation caused by chronic and transitory conditions. Its alcoholic metabolites are formed by carbonyl reductase (CR) and they consist of trans-LOX, which is active, and cis-LOX, which is inactive. In addition, LOX sodium dihydrate can also be converted into an inactive hydroxylated metabolite (OH-LOXs) by cytochrome P450 (CYP) [2].
体内活性	Loxoprofen sodium (4 mg/kg/day; p.o.; 1 or 8 weeks) dihydrate reduces atherosclerosis in mice by reducing inflammation [3]. Loxoprofen sodium (60 μg/mL; p.o.; 24 days) dihydrate suppresses mouse tumor growth by inhibiting VEGF [4]. Animal Model: ApoE -/- mice (C57BL/6J-Apoe tm1Unc ) with high-fat diet (0.2% cholesterol, 21% saturated fat) from 8 to 16 weeks of age [3] Dosage: 4 mg/kg/day in drinking water Administration: Oral dosing from 8 to 16 weeks of age or from 15 to 16 weeks of age Result: Inhibited platelet thromboxane production and platelet aggregation. Reduced extent of atherosclerosis. Suppressed the production of PGE 2, TxB 2 and PGI 2. Animal Model: 6-week-old male C57BL/6 and BDF1 mice, 100 μL suspensions (2 × 10 6 cells/mL) of LLC cells and KLN205 cells were injected subcutaneously into C57BL/6 and BDF1 mice, respectively [4]. Dosage: 60 μg/mL Administration: Oral dosing in drinking water, every day for 24 days Result: Suppressed tumor growth and angiogenesis, suppressed expression of VEGF in mice with LLC tumor, inhibited tubular formation of HUVECs.
存储条件	Shipping with blue ice.

Loxoprofen sodium (dihydrate)|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务